Sign in
Back
Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature
Journal article   Peer reviewed

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature

Mohammed A. Omair, Khalid A. Alnaqbi and Peter Lee
Clinical rheumatology, Vol.31(8), pp.1259-1261
01/08/2012
DOI: https://doi.org/10.1007/s10067-012-2002-8
PMID: 22644089

Abstract

Life Sciences & Biomedicine Rheumatology Science & Technology
Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.

Metrics

1 Record Views

Details